STOCK TITAN

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Viracta Therapeutics (NASDAQ: VIRX) announced participation in the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 10:40 a.m. ET. The event will feature a fireside chat with company leadership, highlighting their focus on precision oncology targeting virus-associated malignancies. The webcast will be available on their website under 'Events and Webcasts' and archived for 30 days. Viracta's lead candidate, Nana-val, is currently in clinical trials for treating Epstein-Barr virus-positive lymphomas and other related cancers.

Positive
  • None.
Negative
  • None.

SAN DIEGO, March 9, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference, on Wednesday, March 16, 2022, at 10:40 a.m. ET.

A webcast of the fireside chat will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 30 days.

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1) as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-301499463.html

SOURCE Viracta Therapeutics, Inc.

FAQ

When is Viracta participating in the Oppenheimer Healthcare Conference?

Viracta Therapeutics will participate in the Oppenheimer Healthcare Conference on March 16, 2022, at 10:40 a.m. ET.

Where can I watch the Viracta conference webcast?

The webcast of the Viracta fireside chat can be found on their investor website under 'Events and Webcasts' and will be available for 30 days.

What is Viracta's lead product candidate?

Viracta's lead product candidate is Nana-val, an all-oral combination therapy currently being evaluated in clinical trials.

What type of malignancies does Viracta target?

Viracta targets virus-associated malignancies, specifically those related to Epstein-Barr virus.

Viracta Therapeutics, Inc.

NASDAQ:VIRX

VIRX Rankings

VIRX Latest News

VIRX Stock Data

9.86M
38.65M
2.84%
50.06%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARDIFF